Welcome to our dedicated page for Lilly Eli & Co news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & Co stock.
Eli Lilly and Company (NYSE: LLY) generates frequent news across cardiometabolic health, oncology, immunology, obesity and manufacturing expansion. This page aggregates recent press releases and third-party coverage so readers can follow how Lilly’s medicines, clinical programs and corporate actions are evolving over time.
Recent updates show Lilly reporting Phase 3 results for multiple late-stage assets. In obesity and cardiometabolic health, the company has shared topline data from ATTAIN-MAINTAIN, a Phase 3 trial of orforglipron, an investigational once-daily oral GLP-1 receptor agonist, for weight maintenance after prior treatment with injectable incretin therapies. Lilly has also reported results from TRIUMPH-4, a Phase 3 trial of retatrutide, an investigational triple agonist targeting GIP, GLP-1 and glucagon receptors, in adults with obesity or overweight and knee osteoarthritis, with co-primary endpoints in weight loss and pain reduction.
In immunology, Lilly has announced positive topline results from the TOGETHER-PsA Phase 3b trial, which evaluated concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) versus Taltz alone in adults with active psoriatic arthritis and obesity or overweight with at least one weight-related condition. The company reports that the combination met the primary endpoint and all key secondary endpoints, supporting an integrated approach to treating psoriatic arthritis and obesity.
Oncology news includes updated EMBER-3 data for Inluriyo (imlunestrant) as monotherapy and in combination with Verzenio (abemaciclib) in ER-positive, HER2-negative advanced breast cancer, and Phase 3 BRUIN CLL-313 results showing that Jaypirca (pirtobrutinib) significantly reduced the risk of progression or death versus chemoimmunotherapy in treatment-naïve CLL/SLL without 17p deletions.
Corporate and strategic news items cover Lilly’s planned acquisition of Ventyx Biosciences, completion of the Adverum Biotechnologies tender offer, a strategic collaboration with Aktis Oncology, and a major manufacturing investment in a new active pharmaceutical ingredient facility in Huntsville, Alabama. Investors and observers can use this news feed to monitor clinical milestones, regulatory submissions, acquisitions, collaborations, financing activities and manufacturing expansions related to LLY.
Eli Lilly (NYSE:LLY) announced positive Phase 3 trial results for Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The BRUIN CLL-314 trial, comparing Jaypirca to Imbruvica (ibrutinib), met its primary endpoint of non-inferiority in overall response rate (ORR), with data favoring Jaypirca (p<0.05).
The groundbreaking study is the first head-to-head Phase 3 trial versus ibrutinib in CLL to include treatment-naïve patients, with this subgroup (n=225) showing particularly strong progression-free survival trends favoring pirtobrutinib. While progression-free survival (PFS) data is not yet mature, early trends favor Jaypirca with no detriment to overall survival.
These results will support future regulatory submissions alongside the upcoming BRUIN CLL-313 Phase 3 study results expected later in 2025.
Eli Lilly (NYSE:LLY) has successfully completed its acquisition of Verve Therapeutics (NASDAQ:VERV), a Boston-based clinical-stage biotechnology company specializing in genetic medicines for cardiovascular disease. The strategic acquisition aims to revolutionize cardiovascular treatment through the development of one-time genetic therapies that could provide lifelong cardiovascular risk reduction.
Led by Ruth Gimeno, Lilly's group vice president of Diabetes and Metabolic Research and Development, this acquisition represents a significant step towards expanding Lilly's presence in the cardiovascular therapeutic space and advancing innovative genetic medicine solutions.
Eli Lilly (NYSE:LLY) has received a positive opinion from the European Medicines Agency's CHMP for donanemab, its treatment for early symptomatic Alzheimer's disease. The recommendation specifically targets adults with confirmed amyloid pathology who are ApoE4 heterozygotes or non-carriers.
The positive opinion was supported by data from the TRAILBLAZER-ALZ 2 and TRAILBLAZER-ALZ 6 clinical trials. The trials demonstrated significant slowing of cognitive decline and reduced disease progression risk. The modified dosing schedule in TRAILBLAZER-ALZ 6 showed lower incidence of ARIA-E while maintaining efficacy.
With 6.9 million Europeans affected by Alzheimer's disease, and this number expected to double by 2050, the European Commission's final regulatory decision is anticipated in the coming months.
Eli Lilly (NYSE:LLY) has scheduled its second-quarter 2025 financial results announcement for August 7, 2025. The company will host a conference call at 8:30 a.m. Eastern time to discuss the quarterly performance with investors, media, and the general public.
The event will be accessible through a live webcast via Lilly's investor relations website, with a replay available after the call.
Eli Lilly (NYSE: LLY) has successfully completed its tender offer for Verve Therapeutics (NASDAQ: VERV). The offer, which expired on July 23, 2025, consisted of $10.50 per share in cash plus one non-tradable contingent value right (CVR) worth up to $3.00 per share upon achieving specific milestones.
The tender offer saw 49,882,464 shares validly tendered, representing approximately 55.7% of Verve's outstanding shares. All conditions of the offer have been met, and Lilly will promptly pay for all validly tendered shares. The acquisition is expected to be finalized on July 25, 2025.
Eli Lilly (NYSE:LLY) has received FDA approval for an updated label with a new dosing schedule for Kisunla (donanemab-azbt), its monthly Alzheimer's treatment. The modified titration schedule demonstrated a 41% reduction in ARIA-E incidents at 24 weeks and 35% reduction at 52 weeks compared to the original dosing.
The new dosing maintains Kisunla's efficacy while improving safety, achieving similar amyloid plaque removal (67% reduction vs. 69% originally) and P-tau217 reduction. The treatment, initially approved in July 2024, has shown to slow cognitive decline by up to 35% in less advanced patients and 22% in the overall population.